Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Tags :Merck
Walder Wyss’ IP team successfully represented the pharmaceutical company Merck in appeal proceedings before the Swiss Federal Supreme Court against its US competitor MSD. The case Following World War I, Merck’s US subsidiary, which
